User Feedback Analysis System using Natural Language Processing and Artificial Intelligence

The Web has dramatically changed the way that people express their views and opinions. Now if one wants to purchase a product, he/she is no longer limited to asking his/her friends and families because there are many product reviews on the Web which give opinions of existing users of the product. Here we present the system which provides us information about such products and services in summarization form. Finding opinion sources and monitoring them on the Web can still be a difficult task because there are a large number of diffrent sources, and each source may also have a huge volume of opinionated text (text with opinions or sentiments). In most cases, opinions are hidden in long forum posts and blogs. It is complicated for a human reader to find relable sources, extract related sentences with opinions, read them, summarize them, and manage them into usable forms. Thus, automated summarization systems are needed. Using this summarization we can recognize the importance, quality, popularity of product and services. In this system we make summarization for product. But, we can use this system anywhere, where text analysis is required. Sentiment analysis, also known as opinion mining, grows out of this need. It is a challenging natural language processing or text mining problem. Due to its tremendous value for practical applications, there has been an excessive growth of both research in academia and applications in the industry

Moving Object Detection in Low-Illuminance Video

The security is a main threat exists in every real-time system. The systems like disaster-prevention, crime-prevention and boarder security needs highly secured mechanism to alert the people about the incident happening in near about area. Camera system is widely used to monitor the area where security is crucial like for disaster-prevention and crime-prevention. However, at low-illuminance condition, the performance of normal cameras is degrade in great extent. At low-illuminance condition night vision cameras are developed and used but they do not support moving object detection. Also the Gaussian filter technique is used in the system requires the large amount of calculation so the time requirement is also large. Therefore, it is conceivable that the Gaussian filter is not suitable for real time video processing. In this system, input which is low-illuminance video is first denoised using a moving average filter. In that candidate regions of moving object are found by differencing between transformed current image and recent previous image. Moving object is finally decided by combined feature set and motion analysis. Object is tracked by matching object components in ROI. In the motion detection for low-light video images, it is possible to improve the accuracy of recognition by intensity correction and noise removal as preparation. After the detection security system will generate the alert

StreetWise: Smart Speakers vs Human Help in Public Slum Settings

This paper explores the use of conversational speech question and answer systems in the challenging context of public spaces in slums. A major part of this work is a comparison of the source and speed of the given responses; that is, either machine-powered and instant or human-powered and delayed. We examine these dimensions via a two-stage, multi-sited deployment. We report on a pilot deployment that helped refine the system, and a second deployment involving the installation of nine of each type of system within a large Mumbai slum for a 40-day period, resulting in over 12,000 queries. We present the findings from a detailed analysis and comparison of the two question-answer corpora; discuss how these insights might help improve machine-powered smart speakers; and, highlight the potential benefits of multi-sited public speech installations within slum environments. © 2019. Copyright held by the authors

Antidiabetic Activity of Gnidia glauca

Diabetes is a metabolic disorder affecting about 220 million people worldwide. One of the most critical complications of diabetes is post-prandial hyper-glycemia (PPHG). Glucosidase inhibitor and α-amylase inhibitors are class of compounds that help in managing PPHG. Low-cost herbal treatment is recommended due to their lesser side effect for treatment of diabetes. Two plants with significant traditional therapeutic potential, namely, Gnidia glauca and Dioscorea bulbifera, were tested for their efficiency to inhibit α-amylase and α-glucosidase. Stem, leaf, and flower of G. glauca and bulb of D. bulbifera were sequentially extracted with petroleum ether, ethyl acetate, and methanol as well as separately with 70% ethanol. Petroleum ether extract of flower of G. glauca was found to inhibit α-amylase significantly (78.56%). Extracts were further tested against crude murine pancreatic, small intestinal, and liver glucosidase enzyme which revealed excellent inhibitory properties. α-glucosidase inhibition provided a strong in vitro evidence for confirmation of both G. glauca and D. bulbifera as excellent antidiabetic remedy. This is the first report of its kind that provides a strong biochemical basis for management of type II diabetes using G. glauca and D. bulbifera. These results provide intense rationale for further in vivo and clinical study

Anti-cancer activities of allyl isothiocyanate and its conjugated silicon quantum dots

Allyl isothiocyanate (AITC), a dietary phytochemical in some cruciferous vegetables, exhibits promising anticancer activities in many cancer models. However, previous data showed AITC to have a biphasic effect on cell viability, DNA damage and migration in human hepatoma HepG2 cells. Moreover, in a 3D co-culture of HUVEC with pericytes, it inhibited tube formation at high doses but promoted this at low doses, which confirmed its biphasic effect on angiogenesis. siRNA knockdown of Nrf2 and glutathione inhibition abolished the stimulation effect of AITC on cell migration and DNA damage. The biological activity of a novel AITC-conjugated silicon quantum dots (AITC-SiQDs) has been investigated for the first time. AITC-SiQDs showed similar anti-cancer properties to AITC at high doses while avoiding the low doses stimulation effect. In addition, AITC-SiQDs showed a lower and long-lasting activation of Nrf2 translocation into nucleus which correlated with their levels of cellular uptake, as detected by the intrinsic fluorescence of SiQDs. ROS production could be one of the mechanisms behind the anti-cancer effect of AITC-SiQDs. These data provide novel insights into the biphasic effect of AITC and highlight the application of nanotechnology to optimize the therapeutic potential of dietary isothiocyanates in cancer treatment

Quantification of three macrolide antibiotics in pharmaceutical lots by HPLC: Development, validation and application to a simultaneous separation

A new validated high performance liquid chromatographic (HPLC) method with rapid analysis time and high efficiency, for the analysis of erythromycin, azithromycin and spiramycin, under isocratic conditions with ODB RP18 as a stationary phase is described. Using an eluent composed of acetonitrile –2-methyl-2-propanol –hydrogenphosphate buffer, pH 6.5, with 1.5% triethylamine (33:7: up to 100, v/v/v), delivered at a flow-rate of 1.0 mL min-1. Ultra Violet (UV) detection is performed at 210 nm. The selectivity is satisfactory enough and no problematic interfering peaks are observed. The procedure is quantitatively characterized and repeatability, linearity, detection and quantification limits are very satisfactory. The method is applied successfully for the assay of the studied drugs in pharmaceutical dosage forms as tablets and powder for oral suspension. Recovery experiments revealed recovery of 97.13–100.28%

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.